Business Context and Reporting Period
This Form 8-K Current Report was filed by Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) on November 13, 2025. The filing addresses Item 5.02 regarding the amendment of the Executive Employment Agreement with Erik Emerson, the Company's Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments rather than financial performance metrics.
Material Changes
Effective November 13, 2025, the Company amended its Executive Employment Agreement with CEO Erik Emerson. The material changes include:
- Base Salary Increase: The annual base salary has been increased to $500,000.
- Severance Enhancement: In the event of termination without cause, the Executive is now entitled to 24 months of base salary and benefits, plus immediate vesting of all unvested equity, contingent upon the execution of a release of claims.
- Forfeiture Clarification: The amendment clarifies that termination for cause or resignation without good reason results in the automatic forfeiture of all unvested equity without payment.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on business outlook, or specific risk factors beyond the standard contractual terms of the employment amendment. The primary contingency noted is the requirement for the Executive to sign a release of claims to receive severance benefits.
Investor Verification Checklist
- Verify the full text of the Amendment to Executive Employment Agreement filed as Exhibit 10.1.
- Confirm the impact of the increased salary and potential severance liability on the Company's future cash flow and equity dilution.
- Review the Company's current cash position to assess its ability to fund the potential 24-month severance package if triggered.